HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Q2

This article was originally published in The Rose Sheet

Executive Summary

Selsun Blue, Gold Bond and Icy Hot contribute to 10% increase in revenues in the fiscal second quarter to $70.1 mil. including royalties, the firm reports June 18. Sales of Selsun Blue jumped 12% in the quarter over the year ago period due to a strong marketing campaign and initial shipments of a new conditioner, while net sales of Gold Bond grew 32%, led by a double-digit increase from the lotion, cream and foot segments, Chattem says. Strong results of some brands were offset by a 55% year-over-year decline in sales of Dexatrim diet pills. Operating income excluding settlement charges related to Dexatrim litigation rose 16% to $19.8 mil., while net income excluding settlement charges and charges related to debt extinguishment soared 41% to $10.6 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel